UPCC 16520: A Phase Ib-II Trial of Tocilizumab | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 1

28 participants needed

1 Location

Brief description of study

This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation). Patients with driver mutations in EGFR, ALK, ROS1, BRAF, or other driver mutations who receive driver mutation-based therapy in 1st line are excluded from the trial.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Lung Cancer
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 844091

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

UPCC 16520: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Brief description of study

Eligibility of study

Find a site

Interested in the study